CClinicalTrials.gg
Status unknownNCT04649281Updated Dec 2, 2020

Insomnia and Sleep Disturbances in Chronic Pain Patients - Relation to Physical Activity Level and Opioid Use

An interventional study of Accelerometry in Chronic Pain, Insomnia and Exercise, sponsored by Göteborg University. Status unknown at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-02.

Sponsored by Göteborg University · Not applicable, Interventional, and Screening

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Pain is one of the most common causes of healthcare contact and long-term sick leave, with negative consequences on physical and mental health. Poor sleep is common in chronic pain patients. Epidemiological studies indicate that 5-7% of patients with chronic pain are treated regularly with strong opioids. Negative side effects of pain modulating drugs on sleep quality have been reported, which may have negative influence on overall disease management in chronic pain patients. However, to date there are conflicting results regarding the effects of opioids on sleep, since the pain relieving effect of opioids seem to affect sleep positively. There is data suggesting that physical activity has positive effects on both pain perception and sleep quality (and duration). The aim of the study is to explore insomnia and characteristics of sleep in patients with chronic pain and the relationship with physical activity level and opioid use.

Read the detailed description

One hundred participants with planned follow-up (decision according to clinical routine) at the Pain Centre will be consecutively recruited. After signed informed consent, the participants will wear two accelerometers during one week, one for recording sleep and one for recording physical activity. The participants will be asked to fill out a sleep and pain diary during the same week. Furthermore, the participants will fill out questionnaires regarding sleep, life style, mental fatigue and self-efficacy. All study participant are included in the Swedish Quality Registry for Pain Rehabilitation (SQRP). Data from the SQRP will be used regarding patient health characteristics, pain and pain associated symptoms, health related quality of life, sleep and self-reported physical activity level. Data regarding co-morbidity, drug use, pharmacological treatment and other interventions at the Pain Center will be collected from the patient charts. In addition, the participants blood pressure and neck circumference will be measured. Blood samples will be analysed for biomarkers associated with pain and sleep disturbance.

02

Conditions studied

  • Chronic Pain
  • Insomnia
  • Exercise
  • Sleep
  • Sleep Disorder
  • Opioid Use

Keywords

  • Accelerometry
  • Mental fatigue
  • Self-Efficacy
03

In context

Sleep Initiation and Maintenance Disorders

1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.

This study's planned enrollment of 100 is above the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Göteborg University is the lead sponsor of 265 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Chronic pain (i.e. pain > 3 months)
  • Planned follow up at the Pain Centre
  • Age ≥18 years
  • Consents to participation in the study

Exclusion criteria

Exclusion Criteria:

  • Inadequate knowledge of the Swedish language
  • Alcohol or substance abuse
  • Severe untreated psychiatric disorders including psychiatric disease and/or psychological conditions which are the primary determinant to the patient's pain condition
  • Malignant disease with short expected survival
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Accelerometry

    Recording of sleep and physical activity by accelerometry during one week.

    Device: Accelerometry

Interventions

  • DeviceAccelerometry

    Recording of sleep and physical activity by accelerometry during one week.

06

What researchers measure

Primary outcomes

  1. Sleep

    Sleep duration in minutes assessed by accelerometry

    Time frame: Daily assessment during one week

  2. Sleep

    Sleep timing, i.e. sleep onset and wake time assessed by accelerometry

    Time frame: Daily assessment during one week

  3. Physical activity

    Minutes of physical activity per week at moderate and vigorous intensity physical activity (MVPA), minutes of sedentary behaviour (SED) assessed by accelerometry

    Time frame: Daily assessment during one week

  4. Opioid consumption

    Opioid consumption in morphine equivalent doses

    Time frame: Opioid consumption at study enrollment

  5. Pain intensity

    Pain intensity according to Numeric Rating Scale (NRS), score from 0 to 10, where 0 is described as "no pain" and 10 as "worst pain imaginable"

    Time frame: Daily assessment during one week

Secondary outcomes

  1. Insomnia Severity

    Total Score from the 7-item Insomnia Severity Index where total score ranges from 0-28 and higher scores indicate greater severity of insomnia.

    Time frame: Insomnia severity at enrollment

  2. Sleep quality

    Assessed with the Pittsburgh Sleep Quality Index (PSQI). The PSQI consists of 19 self-rated questions which assess a wide variety of factors relating to sleep quality, including estimates of sleep duration and latency and of the frequency and severity of specific sleep related problems. The 19 items are grouped into seven component scores, each weighted equally on a 0-3 scale. The seven component score are then summed to yield a global PSQI score which has a range of 0-21; higher scores indicate worse sleep quality.

    Time frame: Sleep quality at study enrollment

  3. Daytime sleepiness

    Epworth Sleepiness Scale (ESS), which quantifies daytime sleepiness. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher daytime sleepiness.

    Time frame: Daytime sleepiness at study enrollment

  4. Self-assessed physical activity

    Minutes of physical activity per week (physical exercise and daily exercise) and minutes of sedentary behaviour per week.

    Time frame: Self-assessed physical activity at study enrollment

  5. Self-efficacy for exercise scale

    The Self-efficacy for exercise scale measures a patient's self-efficacy when it comes to physical exercise. The questionnaire consists of 9 questions that can be answered on a 1-10 scale. A total score between 9 and 90 is calculated, were a higher number represent a better outcome.

    Time frame: Self-efficacy for exercise at study enrollment

  6. Mental fatigue scale

    The mental fatigue scale (MFS) is a multidimensional questionnaire containing 15 questions. A total score between 0-42 is calculated. A score \>10 indicates a problem with mental fatigue.

    Time frame: Mental fatigue at study enrollment

  7. Sleep dairy

    Self-assessed sleep latency, total sleep time, wake time after sleep onset and sleep quality.

    Time frame: Daily assessment during one week

Other outcomes

  1. Neurofilament light

    Neurofilament light in blood sample

    Time frame: Neurofilament light at study enrollment

  2. 25-hydroxyvitamin D

    Levels of Serum 25-hydroxyvitamin D (25\[OH\]D)

    Time frame: 25-hydroxyvitamin D at study enrollment

07

Study locations

1 of 1 sites recruiting
  • Pain Centre, Department of Anaesthesiology and Intensive Care Medicine Östra, Sahlgrenska University Hospital, Region Västra Götaland
    Gothenburg, Sweden
    • Paulin Andréll, MD, PhD · Contact
    • Martin Olsson, MD · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04649281
Lead sponsor
Göteborg University
Collaborators
Vastra Gotaland Region
Responsible party
Sponsor
First posted
Dec 2, 2020
Start date
Oct 12, 2020
Primary completion
Dec 31, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Dec 2, 2020

Study contacts

Paulin Andréll, MD, PhD
Contact
paulin.andrell@gu.se
+46-31-3438259
Martin Olsson, MD
Contact
martin.olsson@gu.se
+46-31-3435816
Paulin Andréll, MD, PhD
principal investigator · Sahlgrenska University Hospital, Region Västra Götaland; Göteborg University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion